Inhibitor binding to topoisomerase II leading to infant leukaemia

This Adverse Outcome Pathway (AOP) describes the linkages between perturbation of normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% all childhood acute lymphoblastic leukaemias) developmental origin, manifesting soon after birth (< 1 year old). The present AOP how interference stressors with DNA can possibly result double-strand break chromosomal rearrangement during intrauterine development lead to leukaemia, birth. proposed supported by number evidences means using etoposide as model compound empirically support linkage molecular initiating event adverse outcome. also identifies several knowledge gaps, main ones being identification cell investigation TopoII poisons robust model; thus, may be modified future on basis new evidence. referred 202 Collaborative Wiki (AOP-Wiki).